Glucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus: A systematic review-Reference-Cited by-同舟云学术

Glucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus: A systematic review

Published:2023-08 Issue: Volume:164 Page:80-89
ISSN:0022-3956
Container-title:Journal of Psychiatric Research
language:en
Short-container-title:Journal of Psychiatric Research

Author:

Cooper Daniel H.^ORCID,Ramachandra Ranuk,Ceban Felicia,Di Vincenzo Joshua D.,Rhee Taeho Greg,Mansur Rodrigo B.,Teopiz Kayla M.,Gill Hartej,Ho Roger,Cao Bing,Lui Leanna M.W.,Jawad Muhammad Youshay,Arsenault Juliet,Le Gia Han,Ramachandra Diluk,Guo Ziji,McIntyre Roger S.

Publisher

Elsevier BV

Subject

Biological Psychiatry,Psychiatry and Mental health

Reference47 articles.

1. Glucagon-like peptide-1 (GLP-1): a gut hormone of potential interest in the treatment of diabetes;Ahrén;Bioessays,1998

2. Exenatide and the treatment of patients with Parkinson's disease;Aviles-Olmos;J. Clin. Invest.,2013

3. Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease;Aviles-Olmos;J. Parkinsons Dis.,2014

4. The association between Diabetes mellitus and Depression;Bădescu;J. Med. Life,2016

5. The association between insulin therapy and depression in patients with type 2 diabetes mellitus: a meta-analysis;Bai;BMJ Open,2018

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of ketamine on metabolic parameters in depressive disorders: A systematic review;Journal of Affective Disorders;2024-12

2. Effects of Glucagon-like Peptide-1 Receptor Agonists on Cardiac Function, Exercise Capacity and Quality of Life;Cardiac Failure Review;2024-09-11

3. Semaglutide: effects on eating behavior;Meditsinskiy sovet = Medical Council;2024-09-02

4. Glucagon-like peptide 1 agonist and effects on reward behaviour: A systematic review;Physiology & Behavior;2024-09

5. GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review;eClinicalMedicine;2024-09